The Experts below are selected from a list of 570 Experts worldwide ranked by ideXlab platform

Bertram Schnitzer - One of the best experts on this subject based on the ideXlab platform.

  • anti cd34 immunoperoxidase staining in paraffin sections of acute leukemia comparison with flow cytometric immunophenotyping
    Human Pathology, 1992
    Co-Authors: Curtis A. Hanson, Charles W Ross, Bertram Schnitzer
    Abstract:

    Anti-CD34 is a monoclonal antibody that reacts with bone marrow progenitor cells and leukemic blasts, and is expressed on 30% to 50% of all acute leukemias. Detection of CD34 has previously been restricted to flow cytometric studies. To expand the utility of CD34, we immunostained 46 paraffin-embedded bone marrow specimens with acute leukemia; results were compared with flow cytometric studies. CD34 reactivity was also evaluated in nine chronic leukemia cases, 27 malignant Lymphoma cases (Hodgkin's disease and non-Hodgkin's Lymphoma), six normal bone marrow specimens, and three benign, Hyperplastic Lymph Node specimens. All cases that were CD34 positive by flow cytometry (11 of 19 B-cell precursor acute Lymphoblastic leukemia cases, one of six T-cell acute Lymphoblastic leukemia cases, and seven of 21 acute myeloblastic leukemia cases) were also CD34 positive in paraffin sections. Both cell membrane and cytoplasmic staining was seen. The positivity percentage and fluorescence intensity by flow cytometry correlated with the estimated number of stained cells and the intensity of immunoperoxidase staining in 18 of 19 CD34-positive cases. The remaining bone marrow and Lymph Node cases studied were CD34 negative; prominent endothelial cell staining, however, was noted. This is the first report of anti-CD34 staining of acute leukemia in paraffin-embedded sections. In contrast to other monoclonal anti-bodies reactive in bone marrow paraffin sections with leukemia, anti-CD34 immunoperoxidase staining is limited to leukemic blasts and may provide useful diagnostic information when flow cytometric studies are not available.

Curtis A. Hanson - One of the best experts on this subject based on the ideXlab platform.

  • anti cd34 immunoperoxidase staining in paraffin sections of acute leukemia comparison with flow cytometric immunophenotyping
    Human Pathology, 1992
    Co-Authors: Curtis A. Hanson, Charles W Ross, Bertram Schnitzer
    Abstract:

    Anti-CD34 is a monoclonal antibody that reacts with bone marrow progenitor cells and leukemic blasts, and is expressed on 30% to 50% of all acute leukemias. Detection of CD34 has previously been restricted to flow cytometric studies. To expand the utility of CD34, we immunostained 46 paraffin-embedded bone marrow specimens with acute leukemia; results were compared with flow cytometric studies. CD34 reactivity was also evaluated in nine chronic leukemia cases, 27 malignant Lymphoma cases (Hodgkin's disease and non-Hodgkin's Lymphoma), six normal bone marrow specimens, and three benign, Hyperplastic Lymph Node specimens. All cases that were CD34 positive by flow cytometry (11 of 19 B-cell precursor acute Lymphoblastic leukemia cases, one of six T-cell acute Lymphoblastic leukemia cases, and seven of 21 acute myeloblastic leukemia cases) were also CD34 positive in paraffin sections. Both cell membrane and cytoplasmic staining was seen. The positivity percentage and fluorescence intensity by flow cytometry correlated with the estimated number of stained cells and the intensity of immunoperoxidase staining in 18 of 19 CD34-positive cases. The remaining bone marrow and Lymph Node cases studied were CD34 negative; prominent endothelial cell staining, however, was noted. This is the first report of anti-CD34 staining of acute leukemia in paraffin-embedded sections. In contrast to other monoclonal anti-bodies reactive in bone marrow paraffin sections with leukemia, anti-CD34 immunoperoxidase staining is limited to leukemic blasts and may provide useful diagnostic information when flow cytometric studies are not available.

Charles W Ross - One of the best experts on this subject based on the ideXlab platform.

  • anti cd34 immunoperoxidase staining in paraffin sections of acute leukemia comparison with flow cytometric immunophenotyping
    Human Pathology, 1992
    Co-Authors: Curtis A. Hanson, Charles W Ross, Bertram Schnitzer
    Abstract:

    Anti-CD34 is a monoclonal antibody that reacts with bone marrow progenitor cells and leukemic blasts, and is expressed on 30% to 50% of all acute leukemias. Detection of CD34 has previously been restricted to flow cytometric studies. To expand the utility of CD34, we immunostained 46 paraffin-embedded bone marrow specimens with acute leukemia; results were compared with flow cytometric studies. CD34 reactivity was also evaluated in nine chronic leukemia cases, 27 malignant Lymphoma cases (Hodgkin's disease and non-Hodgkin's Lymphoma), six normal bone marrow specimens, and three benign, Hyperplastic Lymph Node specimens. All cases that were CD34 positive by flow cytometry (11 of 19 B-cell precursor acute Lymphoblastic leukemia cases, one of six T-cell acute Lymphoblastic leukemia cases, and seven of 21 acute myeloblastic leukemia cases) were also CD34 positive in paraffin sections. Both cell membrane and cytoplasmic staining was seen. The positivity percentage and fluorescence intensity by flow cytometry correlated with the estimated number of stained cells and the intensity of immunoperoxidase staining in 18 of 19 CD34-positive cases. The remaining bone marrow and Lymph Node cases studied were CD34 negative; prominent endothelial cell staining, however, was noted. This is the first report of anti-CD34 staining of acute leukemia in paraffin-embedded sections. In contrast to other monoclonal anti-bodies reactive in bone marrow paraffin sections with leukemia, anti-CD34 immunoperoxidase staining is limited to leukemic blasts and may provide useful diagnostic information when flow cytometric studies are not available.

Kenneth C Anderson - One of the best experts on this subject based on the ideXlab platform.

  • interleukin 6 is required for pristane induced plasma cell hyperplasia in mice
    British Journal of Haematology, 1996
    Co-Authors: Douglas A Dedera, Roderick T Bronson, David P Lebrun, Dharminder Chauhan, Mitsuyoshi Urashima, Kenneth C Anderson
    Abstract:

    Intraperitoneal injection of pristane induces production of interleukin-6 (IL-6) and either plasmacytosis or plasmacytoma in mice, depending upon the genetic background. Pristane does not induce plasmacytoma in IL-6 knockout (IL-6-/-) mice, suggesting that IL-6 is required for this process. In the present study we determined whether IL-6 is also required for pristane-induced hyperplasia of normal plasma cells. Pristane was injected intraperitoneally into IL-6-/- and IL-6 wild-type (IL-6+/+) mice. Overall there were more deaths in IL-6+/+ mice (85%) than in IL-6-/- mice (40%), P = 0.024. Hyperplastic Lymph Node and spleen weight did not differ (P= 0.82 and P=0.15, respectively) in IL-6-/- versus IL-6+/+ mice. Lymphocytosis with similar patterns of expression of B-cell (B220) and T-cell (Thy-1) antigens was noted in both IL-6-/- and IL-6+/+ mice. However, morphological studies, dual fluorescent staining for Syn-1 and B220 antigens (syn-1 + B220 + cells), and intracytoplasmic Ig staining revealed plasma cell hyperplasia in Lymph Node and spleen from IL-6+/+, but not IL-6-/-, mice. These plasma cells from IL-6+/+ mice were polyclonal and unable to induce tumour formation in severe combined immuNodeficient mice. These data demonstrate that IL-6 is required for pristane-induced hyperplasia of polyclonal plasma cells in mice.

Douglas A Dedera - One of the best experts on this subject based on the ideXlab platform.

  • interleukin 6 is required for pristane induced plasma cell hyperplasia in mice
    British Journal of Haematology, 1996
    Co-Authors: Douglas A Dedera, Roderick T Bronson, David P Lebrun, Dharminder Chauhan, Mitsuyoshi Urashima, Kenneth C Anderson
    Abstract:

    Intraperitoneal injection of pristane induces production of interleukin-6 (IL-6) and either plasmacytosis or plasmacytoma in mice, depending upon the genetic background. Pristane does not induce plasmacytoma in IL-6 knockout (IL-6-/-) mice, suggesting that IL-6 is required for this process. In the present study we determined whether IL-6 is also required for pristane-induced hyperplasia of normal plasma cells. Pristane was injected intraperitoneally into IL-6-/- and IL-6 wild-type (IL-6+/+) mice. Overall there were more deaths in IL-6+/+ mice (85%) than in IL-6-/- mice (40%), P = 0.024. Hyperplastic Lymph Node and spleen weight did not differ (P= 0.82 and P=0.15, respectively) in IL-6-/- versus IL-6+/+ mice. Lymphocytosis with similar patterns of expression of B-cell (B220) and T-cell (Thy-1) antigens was noted in both IL-6-/- and IL-6+/+ mice. However, morphological studies, dual fluorescent staining for Syn-1 and B220 antigens (syn-1 + B220 + cells), and intracytoplasmic Ig staining revealed plasma cell hyperplasia in Lymph Node and spleen from IL-6+/+, but not IL-6-/-, mice. These plasma cells from IL-6+/+ mice were polyclonal and unable to induce tumour formation in severe combined immuNodeficient mice. These data demonstrate that IL-6 is required for pristane-induced hyperplasia of polyclonal plasma cells in mice.